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Childhood‑onset dystonia‑causing KMT2B
variants result in a distinctive genomic
hypermethylation profile
Andrea Ciolfi1†, Aidin Foroutan2,3†, Alessandro Capuano4, Lucia Pedace5, Lorena Travaglini1, Simone Pizzi1,
Marco Andreani5, Evelina Miele5, Federica Invernizzi6, Chiara Reale6, Celeste Panteghini6, Maria Iascone7,
Marcello Niceta1, Ralitza H. Gavrilova8, Laura Schultz‑Rogers8, Emanuele Agolini9, Maria Francesca Bedeschi10,
Paolo Prontera11, Matteo Garibaldi12, Serena Galosi13, Vincenzo Leuzzi13, Paola Soliveri14, Rory J. Olson8,
Giovanna S. Zorzi15, Barbara M. Garavaglia6, Marco Tartaglia1* and Bekim Sadikovic2,3,16*

Abstract
Background: Dystonia is a clinically and genetically heterogeneous movement disorder characterized by sustained
or intermittent muscle contractions causing abnormal, often repetitive, movements and/or postures. Heterozygous
variants in lysine methyltransferase 2B (KMT2B), encoding a histone H3 methyltransferase, have been associated with a
childhood-onset, progressive and complex form of dystonia (dystonia 28, DYT28). Since 2016, more than one hun‑
dred rare KMT2B variants have been reported, including frameshift, nonsense, splice site, missense and other in-frame
changes, many having an uncertain clinical impact.
Results: We characterize the genome-wide peripheral blood DNA methylation profiles of a cohort of 18 patients
with pathogenic and unclassified KMT2B variants. We resolve the “episignature” associated with KMT2B haploinsuf‑
ficiency, proving that this approach is robust in diagnosing clinically unsolved cases, properly classifying them with
respect to other partially overlapping dystonic phenotypes, other rare neurodevelopmental disorders and healthy
controls. Notably, defective KMT2B function in DYT28 causes a non-random DNA hypermethylation across the
genome, selectively involving promoters and other regulatory regions positively controlling gene expression.
Conclusions: We demonstrate a distinctive DNA hypermethylation pattern associated with DYT28, provide an epi‑
genetic signature for this disorder enabling accurate diagnosis and reclassification of ambiguous genetic findings and
suggest potential therapeutic approaches.
Keywords: DNA methylation, Episignature, KMT2B, Dystonia 28
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Background
Dystonia is a neurological hyperkinetic movement condition characterized by sustained or intermittent muscle contractions causing abnormal movements and/
or postures. Dystonia’s symptoms can be characterized
based on body location into focal, segmental or generalized forms, as well as into isolated or combined forms,
whether other movement disorders or neurological signs
occur or not [1]. Childhood-onset dystonias, which are
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usually genetically determined and can be characterized
by other additional neuropsychiatric and systemic features, pose a significant diagnostic challenge for clinicians [1].
The advent of high-throughput sequencing has revolutionized the landscape of dystonia’s genetics, enabling identification of several novel disease genes in
the last decade, most of them causing complex forms
[2]. Recently, heterozygous variants in lysine methyltransferase 2B (KMT2B; MIM *606834), encoding a histone H3 methyltransferase, have been associated with a
childhood-onset, progressive and complex form of dystonia named dystonia 28 (DYT28; MIM #617284) [3–5].
Pathogenic KMT2B variants generally are de novo events
and result in loss-of-function of the methyltransferase,
indicating haploinsufficiency as the mechanism of disease [3–6]. Although the pathomechanistic consequences
of KMT2B variants require further study, KMT2B haploinsufficiency is postulated to affect CNS development
and function by perturbing the expression of key genes
involved in neurodevelopment and motor control [7, 8].
Of note, while KMT2B was identified as a dystonia-associated gene only recently, more than one hundred rare or
private heterozygous single nucleotide variants (SNVs)
as well as insertions/deletions (indels) have been identified in this gene, the majority predicted to cause haploinsufficiency [4–6, 9]. A small proportion of bona fide
pathogenic KMT2B variants are missense and have been
reported to affect conserved functional domains of the
protein (i.e., the PHD-like and FYR-N domains). However, a number of clinically unclassified missense variants
have been described and, in a significant proportion of
cases, these variants are inherited from a healthy parent
[3, 6]. Currently, no functional assay is available to classify these variants.
KMT2B belongs to the family of Set1-Trithorax-type
methyltransferases, which are enzymes that specifically
methylate histone 3 at lysine 4 (H3K4) and play a key
role in chromatin remodeling and gene expression [10].
Mammals possess six SET-related H3K4 methyltransferases (i.e., KMT2A (MLL1), KMT2B (MLL2), KMT2C
(MLL3), KMT2D (MLL4), SETD1A and SETD1B), which
are dynamically regulated during cell-type specification, in a spatially and temporally non-redundant way [7,
11]. H3K4 can be mono- (H3K4me1), di- (H3K4me2)
and tri-methylated (H3K4me3), with each modification
differentially distributed in promoters, enhancers and
other regulatory regions of actively transcribed genes
[12]. While SETD1A and SETD1B are major contributors of global histone H3K4 tri-methylation (H3K4me3),
KMT2B and KMT2A H3K4me3 marks occur at the transcription start site (TSS) regions of a more restricted set
of genes. Different from the other members of the KMT2

Page 2 of 11

family, KMT2C and KMT2D catalyze H3K4me1/2, which
are particularly enriched at enhancers [12].
There is a growing evidence that variants in genes
encoding proteins involved in the maintenance of chromatin remodeling show unique DNA methylation
(DNAm) patterns (known as “episignatures” or EpiSigns), and that these DNAm signatures can be used as
highly specific and robust biomarkers for an increasing
number of disorders caused by mutations in these genes
[13–16]. These genome-wide DNAm signatures currently
include over 40 rare neurodevelopmental disorders associated with more than 60 genes [13, 17]. Of note, these
disease-specific episignatures are detectable in peripheral
blood despite the variable nature and complexity of diseases and the high variance characterizing the DNAm of
genomes from different cells and tissues [13, 17]. As such,
DNA methylation testing has recently been implemented
in clinical diagnosis of patients with rare disorders [17].
By characterizing the genome-wide DNA methylation profiles of a cohort of clinically and genetically confirmed DYT28 patients, here we define a disease-specific
episignature for this disorder and show that the identified methylation pattern could be successfully used to
classify KMT2B variants of uncertain significance (VUS)
and help diagnose clinically unsolved cases. We also
provide evidence that dysfunctional KMT2B in DYT28
causes DNA hypermethylation of promoters and other
regulatory regions positively controlling gene expression,
which collectively points out toward a general repression
of transcriptional activity as pathogenic mechanism in
DYT28.

Methods
Study cohort

The study included eight case individuals (five females
and three males) with bona fide pathogenic KMT2B
variants and clinically confirmed DYT28 (labelled as
DYT28_Pathogenic), and 10 subjects (seven females and
three males) showing variable clinical phenotypes and
KMT2B VUS (labelled as DYT28_VUS), according to
the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP)
guidelines for interpretation of genomic sequence variants [18] (Additional file 9: Table S1). Additionally, nine
control samples were also used (labelled as Control_Testing). The study was approved by the Ospedale Pediatrico
Bambino Gesù Ethical Committee (1702_OPBG_2018)
and the Western University Research Ethics Board (REB
106302). All DNA samples and clinical records were
pseudonymized. DNA specimens were collected following procedures in accordance with the ethical standards
of the declaration of Helsinki protocols, with signed
informed consents from the participating subjects/
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families. Peripheral blood DNA was extracted using
the salting out procedure [19] (patients 1, 2, 5–11, 14
and 18) or the Qiagen DNA extraction kit (patients 3,
4, 12, 13, 15–17). All variants had been confirmed by
Sanger sequencing using the Big-Dye terminator reaction Kit v.1.1 on a 3100XL Genetic Analyzer Automated
Sequencer (Applied BioSystems) (patients 1, 2, 5–11, 14
and 18) or using the Big-Dye terminator reaction Kit v.3.1
on a SeqStudio Genetic Analyzer (Applied Biosystems)
(patients 3, 4, 12, 13, 15–17) (Additional file 1: Figure S1).
DNA methylation profiling and data analysis

Following bisulfite conversion, samples were analyzed
using Illumina Infinium MethylationEPIC BeadChips,
according to the manufacturer’s protocol. Data analysis
was carried out as previously reported [13, 14]. Briefly,
IDAT files containing methylated and unmethylated signal intensity were imported into R v.4.0.2 for analysis following normalization with background correction using
the minfi package [20]. Probes located on X/Y chromosomes or known to cross-react with chromosomal locations other than their target regions contain SNPs at
or near the CpG sites, and suggested by Illumina to be
cross-reactive were excluded, resulting in 776,314 probes
remaining for the analysis. Arrays having more than 5%
probe failure rate and those that were previously identified in our database to impose batch effect were excluded
from the analysis. Sex of the two unknown samples was
predicted using minfi package [20], whereas for the age
estimation the wateRmelon package was used [21]. The
eight samples with DYT28-causing KMT2B variants
(DYT28_Pathogenic) were used to identify the episignature, while the 10 additional samples (DYT28_VUS) were
used for validation and classification by blind testing
(Additional file 9: Table S1).
Principal component analysis (PCA) was performed
to inspect any batch effect and identify outlier samples. MatchIt package was used to select best-matching
controls from EPIC arrays in the EpiSign Knowledge
Database (EKD) at the London Health Sciences Center
(LHSC) considering age, and sex, as matching variables,
providing a control sample size seven times larger than
that of tested cases (56 controls labelled as Control_
Training) [13, 17]. The control cohort characterization is
provided in Additional file 10: Table S2.
Methylation levels (beta values) were converted to
M-values, which were used for linear regression modeling by means of empirical Bayes moderated t-statistic
corrected for false discovery rate (FDR) using the Benjamini-Hochberg (BH) method (limma package [22])
to identify differentially methylated probes (DMPs).
Estimated blood cell proportions for each sample were
added to the model matrix to reduce the bias associated
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with those confounding variables [23]. The most
informative 1,000 probes were identified considering
the interaction between the effect size (absolute mean
methylation difference between DYT28 samples and
batch controls) and p-value [13, 14]. Receiver’s operating curve characteristic analysis was performed to identify the top 500 of these 1000 probes, then probes with
a Pearson’s pairwise correlation > 0.9 were removed,
resulting in identification of 196 independent probes.
Hierarchical clustering was performed using the
gplots package. Multidimensional scaling (MDS) was
performed by scaling of the pairwise Euclidean distances between samples. The e1071 R package was used
to train a support vector machine (SVM) and for construction of a prediction model to calculate what we
refer to as “methylation variant pathogenicity” (MVP)
scores [13]. The eight samples with DYT28, and samples from the EKD databases split into two cohorts,
75% of control subjects (> 1000 individuals) and 75%
of patients from 38 other neurodevelopmental disorders/rare diseases (NDDs/RDs) in the EKD (> 1000
individuals) were used as training set. The remaining
25% control subjects and patients with KMT2B VUS
were considered as the testing set (Additional file 9:
Table S1), in order to improve the specificity of the
classifier. An MVP plot was generated to assess specificity of the classification model.
Functional analysis of differentially methylated regions

To detect the differentially methylated regions (DMRs),
the DMRcate package was used [24], and regions containing at least five different CpGs within 1 kb with a
minimum methylation difference of 10% and a Fisher’s
multiple comparison P < 0.01 were selected. Functional
analysis of differentially methylated regions was performed by means of missMethyl R package [25] and WebGestalt [26]. Genomic region enrichment with respect to
the EPIC annotation manifest for the episignature probes
was calculated by means of Fisher’s exact test; for the
region-level analysis of DMRs, we took advantage of bedTools (v.2.30) [27] Fisher command, considering DMRs
showing overlapping fraction > 50% with the genomic
regions annotated as 5’UTR, TSS1500, TSS200, 1stExon,
Body, 3’UTR regions. DMRs comparison to the 127 reference epigenomes from the NIH Roadmap Epigenomics Consortium was carried out by means of GIGGLE,
a fast and highly scalable genomic interval searching
strategy, and evaluated using the GIGGLE score, that
combines the estimation of the enrichment for observed
versus expected (odds ratio), and Fisher’s two tailed tests
p-value [28].
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Results
DYT28 is associated with hypermethylated DNA
episignature in blood

Eight individuals carrying bona fide pathogenic variants in KMT2B (NM_014727.2), as per the ACMG/AMP
guidelines [18], were included in the study. These variants
can be considered as representative of the DYT28-causing KMT2B variants, as they included frameshift changes
(Pt. 1–4 and 7), in-frame deletions (Pt. 6), and missense
substitutions (Pt. 5 and 8) (Additional file 9: Table S1).
Variants in Pt. 1, 2, 5–8 had been identified by WES in
a cohort of 65 patients with genetically unclassified
childhood-onset dystonia [3, 5, 6, 9]. The two frameshift
variants in Pt. 3 and 4, both resulting in premature termination, were identified in the frame of diagnostic genetic
testing. The clinical and molecular characterization of the
DYT28 cohort is reported in Additional file 9: Table S1.
Comparison of DNA methylation patterns between
the peripheral blood DNA specimens of these 8 samples and 56 controls selected from our database based
on matching for age and sex resulted in identification
of 196 DMPs (methylation difference > 10%, FDR < 0.01,
adjusted for blood cell-type compositions). Notably,
more than 96% of probes (189 out of 196) exhibited relative hypermethylation (Additional file 11: Table S3). Of
note, while the most robust and significant methylation
change described in this episignature classifier involved
hypermethylated regions in DYT28 (Additional file 2:
Figure S2), the majority of the probes in these samples
were found as slightly hypomethylated compared to the
control group (Additional file 3: Figure S3). In order to
assess the robustness of the episignature in differentiating
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between case and control samples, hierarchical clustering (Fig. 1A) and MDS analysis (Fig. 1B) were performed,
resulting in clear separation between groups. Eight
rounds of cross-validation on MDS plot were performed
using different combinations of samples with pathogenic
KMT2B variants (n = 7) as training set and single samples
with pathogenic variants as testing set. In all steps, the
testing samples were correctly clustered with the training
samples further providing evidence of a robust common
DNA methylation signature (Additional file 4: Figure S4).
While the two DYT28-associated missense variants identified in Pt. 5 and Pt.8 satisfied the ACMG/AMP criteria
as bona fide pathogenic variants [18], the same analysis
was also performed excluding those patients (Additional
file 5: Figure S5). Comparison of the DNA methylation
patterns of these six samples and the same 56 ControlTraining samples confirmed the previous results.
The DYT28‑specific episignature allows functional
classification of KMT2B variants

The generated DYT28-specific episignature was used to
test 10 samples with unclassified KMT2B variants that
had been identified in diagnostic genetic testing (Additional file 9: Table S1). Among these variants, two missense substitutions, for which the inheritance pattern
could not be established, had been found in two subjects with childhood-onset dystonia fitting DYT28 (Pt.
9 and 10). Two missense variants, both inherited from
an apparently unaffected parent, had previously been
reported in subjects with DOPA-responsive cervical and
mandibular dystonia (Pt. 14) and slowly progressive dystonia and dyskinesias with caudo-rostral progression (Pt.

Fig. 1 DYT28 episignature identification. A Hierarchical clustering with Ward’s method on Euclidean distance was performed. In the heatmap plot,
each row illustrates a selected CpG site, and each column depicts a sample. The heatmap color scale indicates the range of methylation level; from
blue (no methylation or 0) to red (full methylation or 1). The detected episignature clearly differentiates between samples with pathogenic KMT2B
variants and controls. B The first two dimensions of a MDS plot using the selected probes separate the samples with pathogenic variants in KMT2B
from control samples. Blue circles represent control subjects and red circles indicate subjects with pathogenic KMT2B variants and a confirmed
diagnosis of DYT28. Ellipses indicate 95% confidence interval
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18) without decisive evidence for clinical relevance [3, 9].
Patient 13, who was characterized by progressive generalized dystonia with caudo-cranial progression, presented with an in-frame duplication previously reported
as VUS in ClinVar (VCV000808518.4), and annotated
in gnomAD v.2.1 (MAF = 1.18 × 10−3). The only other
variant that had previously been reported in the general
population was p.Ser2390Leu identified in patient 15
(MAF = 4.02 × 10−5, gnomAD), who showed gait instability and dystonia of the upper and lower limbs during
paroxysmal attacks. Finally, we selected four additional
private missense variants predicted as pathogenic by
CADD [29] and MetaDome [30] algorithms (Additional
file 9: Table S1) in patients showing late-onset dystonia
(Pt. 11 and 12) and congenital movement disorders (Pt.
16 and 17). The de novo occurrence of these variants
could be ascertained only in two cases (Pt. 16 and 17).
The genome-wide methylation data obtained from
blood DNA specimens of the 10 patients with heterozygous KMT2B VUS (Pt. 9 to 18) were analyzed by hierarchical clustering and MDS analysis using the 196
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informative probes defining the DYT28-specific episignature (Fig. 2A, B). Two samples of the testing set (Pt. 9
and 10) clustered with the DYT28 cohort, seven grouped
with controls and one sample (Pt. 18) showed an intermediate position.
To test the use of the episignature in a clinical setting,
the recently developed SVM-based classifier was used
[13, 17], trained by comparing the eight samples with
bona fide pathogenic variants (Pt. 1–8) against the 10
VUS samples (Pt. 9–18), controls and a large set of individuals affected by various forms of NDDs or other RDs
included in the EKD. All patients from other NDDs/RDs
and controls were classified with low probability scores,
indicating the high level of specificity of the DYT28 classifier (Fig. 2C). Consistent with the MDS and hierarchical clustering analyses, two missense KMT2B VUS,
p.Ser1615Leu and p.Arg1777Pro (Pt. 9 and 10), were
classified as disease-causing, while all other variants were
scored with a significantly lower score, ruling out their
clinical relevance in DYT28. Interestingly, the DYT28related missense variants did not show a preferred

Fig. 2 DNA methylation pattern analysis yields full sensitivity and specificity in classifying individuals affected by DYT28. Hierarchical clustering
analysis (A) and MDS (B) plots are used to classify VUS (used as the testing set) with respect to pathogenic KMT2B variants and control samples
(used as the training set). C A support vector machine (SVM) was used to classify samples and calculate probability scores reaches full sensitivity
and specificity for KMT2B variants. The classifier was trained using pathogenic variants, controls and other NDDs/RDs. 75% of controls and NDD/RD
samples used for training (blue), 25% for testing (grey). Ellipses indicate 95% confidence interval
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localization in putative constrained regions and functional domains along the protein sequence. Nevertheless,
we noted the existence of an apparent mutational hotspot for the four pathogenic missense variants between
codons 1,615 and 1,777 (Fig. 3), similarly to what previously reported in the literature [3]. The clinical re-evaluation of patients 11 to 18 documented features or a natural
history of disease that did not fit the classical presentation of DYT28, clinically validating the conclusions based
on the episignature analysis (Additional file 9: Table S1).
Of note, the same validation analysis was performed
considering the episignature generated excluding Pt.5
and Pt.8 (Additional file 6: Figure S6). As shown, hierarchical clustering and MVP classifier properly classified
Pt.5, Pt.8, Pt.9 and Pt.10 within the DYT28 group, further
documenting the robustness of the approach. An apparently lower specificity, however, was provided by MDS
analysis, confirming the dependency of the signature
classification efficacy/specificity on sample size.
DYT28‑causing KMT2B variants are associated
with a non‑random distribution of hypermethylation
in the genome

H3K4 trimethylation is highly enriched at active promoters near TSS and is positively correlated with transcription [10, 11, 31, 32]. Since this non-random distribution
of H3K4me3 throughout the genome, we assessed the
genome-wide distribution of DMRs (defined as stretches
harboring ≥ 5 consecutive CpGs) in DYT28. The analysis
allowed us to identify significant methylation changes in
146 genomic regions (hg19 genome assembly), the vast
majority represented by relative hypermethylation in Pt.1
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to Pt.8 (144 out of 146; Additional file 12: Table S4, Additional file 7: Figure S7). Considering all probes contained
in these 146 regions, we first assessed the overall fit of the
methylation patterns characterizing the 10 samples with
KMT2B VUS with those obtained for the DYT28 and
control groups (Additional file 8: Figure S8). As shown,
the methylation levels for Pt.9 and Pt.10 were more similar to those characterizing patients carrying pathogenic
KMT2B variants (93 and 89% of probes, respectively),
while Pt.11–18 clearly diverge from the DYT28-specific
pattern for a significant proportion of probes (from 55 to
12% of probes with methylation levels similar to DYT28).
These data further validate the ability of the identified
episignature in functionally classifying the tested KMT2B
VUS.
Aiming to functionally characterize the genomic methylation differences in DYT28, we performed gene set
enrichment analyses considering the genes mapping
within DMRs by means of missMethyl [25] and WebGestalt [26] tools, failing to identify any enrichment for
specific biological pathways (MSigDB’s hallmark, Gene
Ontology, KEGG, Reactome, Panther pathways), including those functionally linked to neurodevelopment and
neuronal physiology (data not shown). To further gain
insights on the functional implications of the observed
hypermethylated status associated with defective KMT2B
function, we then explored the hypothesis of a non-random distribution of DNA hypermethylation in genomic
regions typically enriched in H3K4me3, such as promoters. First, we noted that DMPs constituting the episignature were enriched for genomic regions that are generally
poorly methylated in actively transcribed genes (e.g., gene

Fig. 3 KMT2B missense variants distribution. The diagram on the top illustrates the KMT2B’s tolerance to missense changes landscape according
to MetaDome web server. The protein structure is depicted on the bottom, along with the missense variants analyzed in the present work. Purple
boxes indicate protein domains. Green bars depict mutated residues. Known pathogenic variants are written in black [9]; variants classified as
disease-causing in this work (red) and those classified as benign (blue) by the identified episignature are also shown
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promoters [TSS1500] and first exon regions [1stExon])
(Fig. 4A). Consistently, gene body regions, which are
known to be positively correlated with gene expression
when methylated, where significantly underrepresented
(Fig. 4A). To further delve into these results, all probes
located within the annotated gene regions encompassing
the identified DMRs were tested for enrichment analysis
(Fig. 4B, Additional file 12: Table S4). Consistently, we
observed a qualitatively similar pattern of enrichment
involving promoter regions coupled with a depletion of
gene body regions (Fig. 4B).
To further support the correlation between DNA methylation levels in DYT28 and the H3K4me3 epigenetic
modification, we assessed the overlap of DMRs against
the 127 reference epigenomes representing all major cell
lineages in human body generated by the NIH Roadmap
Epigenomics Consortium [12]. This analysis allowed us to
inspect the enrichment of DMRs for regions specifically
marked by H3K4me3 (i.e., active TSSs) and the other 15
associated chromatin states as defined by the consortium
(Fig. 5). The analysis documented a clear enrichment for
the chromatin states associated to H3K4me3 marks (i.e.,
active TSS and flanking active TSS) (Pairwise Wilcoxon
Test’s adjusted p-value < 2.1 10−7), while regions in quiescent state were consistently underrepresented (Fig. 5).

Discussion
Here we report that DYT28 is associated with a genomewide hypermethylated profile, showing that the identified methylation episignature can be successfully used
to diagnose this disorder. DYT28 is a recently identified
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form of dystonia caused by heterozygous inactivating
KMT2B variants. The disorder is generally characterized
by initial lower limb involvement during childhood followed by a more general involvement, usually including
the bulbar and cranio-cervical muscles leading to dysarthria and dysphonia [3, 6]. Of note, the clinical phenotype associated with KMT2B variants is emerging as
variable and has been reported to include conditions not
manifesting dystonia at all [6]. Given the variable phenotypic presentation, lack of validated biomarkers and
scarcity of experimental assays to promptly and straightforwardly assess KMT2B function, current interpreting
of the clinical relevance of KMT2B variants can be challenging. In line with these considerations, bioinformatic
strategies recently proposed showed lack of specificity
[6, 33]. Although protein truncating variants and wholegene deletions classification under a haploinsufficiency
paradigm could be straightforward, caution is needed for
missense changes and in-frame indels in a clinical setting. Indeed, even using combination of state-of-the-art
in silico prediction algorithms (e.g., CADD [29]), regional
constraint analyses (MetaDome [30]), as well as segregation and population frequency data, did not help to identify bona fide pathogenic variants among the subset of
KMT2B missense variants included in this study.
The identified episignature in peripheral blood DNA of
DYT28 patients is defined by a relatively small number
of hypermethylated CpG sites (< 200) and proved to be
robust and effective in classifying DYT28 patients, with
respect to other partially overlapping dystonic phenotypes, other NDDs/RDs, as well as healthy controls. By

Fig. 4 DYT28 is characterized by a hypermethylation pattern on specific gene regions. Histograms illustrate the non-random gene region
distribution for episignature’s probes (A), and DMRs (B) in DYT28 patients. Fisher’s exact test was used to report the statistical significance of the
enrichment/depletion with respect to genomic background (EPIC array). TSS200, transcription start sites 1–200; TSS, transcription start sites 201–
1500; IGR, intergenic regions. A Percentage and statistical significance of feature enrichment for DYT28 episignature: *P < 0.01; **P < 10−3 ***P < 10−6;
B Percentage and statistical significance of feature enrichment for DMRs in DYT28 patients: *P < 0.05; **P < 0.01 ***P < 0.001
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Fig. 5 DMRs enrichment for 15 chromatin states in 127 reference epigenomes in DYT28. Boxplots display enrichment scores (GIGGLE combo
scores) distribution for 15 chromatin states as defined by the NIH Roadmap Epigenomics project. The active states (associated with expressed
genes) consist of active transcription start site (TSS) proximal promoter states (Active TSS and Flanking Active TSS), a transcribed state at the 5′
and 3′ end of genes showing both promoter and enhancer signatures (Transcription at 5’ and 3’), actively transcribed states (Strong Transcription
and Weak Transcription), enhancer states (Enhancers and Genic Enhancers) and a state associated with zinc finger protein genes (ZNF genes and
repeats). The inactive states consist of constitutive heterochromatin, bivalent regulatory states (Bivalent poised TSS, Flanking bivalent TSS enhancers
and Bivalent enhancers), repressed PolyComb states (Repressed PolyComb and Weak Repressed PolyComb) and a quiescent state

using this episignature, we correctly classified missense
changes not residing in constrained regions (Pt. 8) [30,
34], and excluded pathogenicity in cases with partially
overlapping phenotype, or heterozygous for low-frequency alleles predicted as deleterious by in silico algorithms with unknown segregation (Pt. 15) [29, 30, 35], or
documented to occur as de novo events (Pt. 16 and 17).
Of note, our classification algorithm rejected a diagnosis
of DYT28 in patient 18, who carried the p.Arg1003Gln
variant in KMT2B, previously reported as VUS and predicted to have a destabilizing structural effect by homology modeling [9]. We would note, however, that while a
confirmation of a related episignature in a patient with
a genetic VUS is considered strong functional evidence
for pathogenicity under the PS3/BS3 criterion [13, 17],
using the ACMG/AMP sequence variant interpretation
framework [18, 36], a negative result in a patient with or
without a known genetic variant, while indicative, does
not rule out pathogenicity. Although majority of the
genes with episignatures currently have a single common
episignature mapped, genes with multiple episignatures
have been described, and assessment of pathogenicity of
variants outside the established reference range warrants
caution [17].
The present epigenomic analysis also provides relevant insights on the molecular effects of DYT28-causing
KMTB2 variants. A significant genome-wide shift in DNA
methylation was documented: this hypermethylated

status was not associated with a specific enrichment of
biological pathways but was characterized by a significant overrepresentation of regulatory regions known to
be inversely correlated with gene expression (i.e., gene
promoters, and first exons) [11, 37, 38], and a depletion of gene-body regions, where a positive correlation
between DNA methylation and active transcription has
been described [11, 39]. This non-random hypermethylation pattern is opposite of the relative enrichment of
nucleosomes with H3K4me3, which is prominent in TSS
of actively transcribed loci [10–12, 40]. Based on the key
role of KMT2B in H3K4me3, our findings provide new
evidence that dysfunctional KMT2B in DYT28 causes
specific DNA hypermethylation of promoters and other
regulatory regions positively controlling gene expression,
which collectively points out toward a general repression of transcriptional activity in DYT28. This finding has
potentially relevant implications in terms of therapy, as it
points to the use of nonspecific DNA methyltransferase
inhibitors (e.g., 5-aza-2’-deoxycytidine) or small molecules specifically targeting KDM5 demethylases (e.g.,
CPI-455), as a potential approach to restore proper DNA
methylation levels in DYT28 [41].

Conclusions
In summary, we demonstrate evidence of a distinct DNA
methylation episignature associated with KMT2B-related
DYT28, enabling accurate diagnosis and reclassification
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of ambiguous genetic findings. We also provide insights
into the molecular pathophysiology of this disorder,
documenting that KMT2B haploinsufficiency causes
specific DNA hypermethylation of promoters and other
regulatory regions positively controlling gene expression,
pointing to the use of DNA methyltransferase inhibitors
or molecules targeting KDM5 demethylases as potential
therapeutic approaches in DYT28.
Abbreviations
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(A) and MDS (B) plots are used to classify VUS/and likely pathogenic mis‑
sense variants (used as the testing set) with respect to pathogenic KMT2B
variants in Pt.1-4,6,7 and control samples (used as the training set). (C) A
support vector machine (SVM) was used to classify samples and calculate
probability scores reaching full sensitivity and specificity for identifying
pathogenic KMT2B variants. The classifier was trained using bona fide
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pathogenic KMT2B variants, controls and other NDDs/RDs. 75% of controls
and NDD/RD samples used for training (blue), 25% for testing (grey).
Ellipses indicate 95% confidence intervals.
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DYT28. For each significant differentially methylated genomic region, the
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1-8), used to define the episignature, versus 56 control samples. Mean
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